Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications

Expert Rev Hematol. 2017 Feb;10(2):123-135. doi: 10.1080/17474086.2017.1271318. Epub 2016 Dec 26.

Abstract

Mature B-cell lymphoma represents the most common type of Non-Hodgkin lymphoma, and different subtypes prevail at different patient ages. Areas covered: We review recent data on differences and commonalities in mature B-cell lymphoma occurring in adult and pediatric patients, with a special emphasis on molecular advances and therapeutic implications. To this end, we will discuss knowledge on diffuse large B-cell lymphoma and Burkitt lymphoma/leukemia, which are the most frequent subtypes in adult and pediatric patients, respectively, and on primary mediastinal B-cell lymphoma, which is a subtype of mature B-cell lymphoma occurring mainly in adolescents and young adults with a female predominance. Expert commentary: Molecular profiling has revealed molecular alterations that can be used to further classify the subtypes of mature B-cell lymphoma. These new subgroups frequently respond differentially to targeted therapeutic strategies. Future clinical trials utilizing new drugs will address this issue by combining clinical data and response assessment with a molecular workup of the corresponding lymphomas.

Keywords: Mature B-cell lymphoma; demographic factors; molecular profiling; targeted therapies; treatment optimization.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / metabolism
  • Cell Transformation, Neoplastic / pathology
  • Combined Modality Therapy
  • Diagnosis, Differential
  • Disease Progression
  • Humans
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / epidemiology
  • Lymphoma, B-Cell / etiology
  • Lymphoma, B-Cell / therapy*
  • Neoplasm Grading
  • Prognosis
  • Standard of Care
  • Treatment Outcome